

**SEC. \_\_\_\_ COUNTRY OF ORIGIN LABELING ON PRESCRIPTION DRUGS.**

(a) IN GENERAL.—Not later than 90 days after the date of enactment of this Act, the Secretary of Health and Human Services shall issue regulations to require that the labeling, including retail packaging, of each prescription drug include the name of the country in which such prescription drug was manufactured.

(b) DEFINITION.—In this section, the term “labeling” has the meaning given such term in section 201(m) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(m)).

**SA 1062.** Mr. DORGAN (for himself and Ms. SNOWE) submitted an amendment intended to be proposed by him to the bill S. 1082, to amend the Federal Food, Drug, and Cosmetic Act to reauthorize and amend the prescription drug user fee provisions, and for other purposes; which was ordered to lie on the table; as follows:

At the appropriate place in the amendment, insert the following:

**SEC. \_\_\_\_ CERTIFICATION OF SAFETY FOR NEW PRESCRIPTION DRUGS.**

Notwithstanding any other provision of law, the Secretary of Health and Human Services shall certify, prior to the approval for marketing of any new prescription drug under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), that the approval of such drug poses no additional risk to the public's health and safety.

**SA 1063.** Mr. DORGAN (for himself and Ms. SNOWE) submitted an amendment intended to be proposed by him to the bill S. 1082, to amend the Federal Food, Drug, and Cosmetic Act to reauthorize and amend the prescription drug user fee provisions, and for other purposes; which was ordered to lie on the table; as follows:

At the appropriate place in the amendment, insert the following:

**SEC. \_\_\_\_ COUNTERFEIT-RESISTANT TECHNOLOGIES.**

(a) IN GENERAL.—Notwithstanding any other provision of this Act, the requirement that the Secretary of Health and Human Services certify that the implementation of the title of this Act relating to the Importation of Prescription Drugs will pose no additional risk to the public's health and safety and will result in a significant reduction in the cost of covered products to the American consumer shall not apply to the requirement that the Secretary, not later than 18 months after the date of enactment of this Act, require that the packaging of any prescription drug incorporate—

(1) a standardized numerical identifier unique to each package of such drug, applied at the point of manufacturing and repackaging (in which case the numerical identifier shall be linked to the numerical identifier applied at the point of manufacturing); and

(2)(A) overt optically variable counterfeit-resistant technologies that—

(i) are visible to the naked eye, providing for visual identification of product authenticity without the need for readers, microscopes, lighting devices, or scanners;

(ii) are similar to that used by the Bureau of Engraving and Printing to secure United States currency;

(iii) are manufactured and distributed in a highly secure, tightly controlled environment; and

(iv) incorporate additional layers of non-visible convert security features up to and including forensic capability, as described in subsection (b); or

(B) technologies that have a function of security comparable to that described in subparagraph (A), as determined by the Secretary.

(b) STANDARDS FOR PACKAGING.—For the purpose of making it more difficult to counterfeit the packaging of drugs subject to this section, the manufacturers of such drugs shall incorporate the technologies described in subsection (a) into at least 1 additional element of the physical packaging of the drugs, including blister packs, shrink wrap, package labels, package seals, bottles, and boxes.

**SA 1064.** Mr. SESSIONS submitted an amendment intended to be proposed to amendment SA 1059 submitted by Mr. SESSIONS (for himself, Mrs. LINCOLN, Mr. COCHRAN, Mr. PRYOR, Mr. LOTT, and Mr. SHELBY) and intended to be proposed to the bill S. 1082, to amend the Federal Food, Drug, and Cosmetic Act to reauthorize and amend the prescription drug user fee provisions, and for other purposes; which was ordered to lie on the table; as follows:

On page 1 of the amendment, strike line 4 and all that follows through line 7 on page 2, and redesignate the remaining subsections accordingly.

**NOTICES OF HEARINGS/MEETINGS****COMMITTEE ON INDIAN AFFAIRS**

Mr. DORGAN. Mr. President, I would like to announce that the Committee on Indian Affairs will meet on Thursday, May 10, 2007, at 9:30 a.m. in Room 485 of the Russell Senate Office Building to conduct a business meeting.

Those wishing additional information may contact the Indian Affairs Committee at 224-2251.

**COMMITTEE ON ENERGY AND NATURAL RESOURCES**

Mr. BINGAMAN. Mr. President, I would like to announce for the information of the Senate and the public that an oversight hearing has been scheduled before the Committee on Energy and Natural Resources.

The hearing will be held on Tuesday, May 15, 2007, at 10 a.m. in room SD-366 of the Dirksen Senate Office Building.

The purpose of this hearing is to receive testimony on the short-term energy outlook for the summer of 2007 for oil and gasoline.

Because of the limited time available for the hearing, witnesses may testify by invitation only. However, those wishing to submit written testimony for the hearing record should send two copies of their testimony to the Committee on Energy and Natural Resources, United States Senate, Washington, DC 20510-6150, or by email to [rachel.paternack@energy.senate.gov](mailto:rachel.paternack@energy.senate.gov).

For further information, please contact Tara Billingsley at (202) 224-7571 or Rachel Paternack at (202) 224-0883.

**AUTHORITY FOR COMMITTEES TO MEET****COMMITTEE ON COMMERCE, SCIENCE, AND TRANSPORTATION**

Mrs. MURRAY. Mr. President, I ask unanimous consent that the Com-

mittee on Commerce, Science, and Transportation be authorized to hold a business meeting during the session of the Senate on Tuesday, May 8, 2007, at 10 a.m., in room 253 of the Russell Senate Office Building. The purpose of this meeting will be to consider and approve S. 357, the Ten-in-Ten Fuel Economy Act of 2007.

The PRESIDING OFFICER. Without objection, it is so ordered.

**COMMITTEE ON FINANCE**

Mrs. MURRAY. Mr. President, I ask unanimous consent that the Committee on Finance be authorized to meet during the Session of the Senate on Finance will meet on Tuesday, May 8, 2007, at 10 a.m., in 215 Dirksen Senate Office Building, to hear testimony on “The Medicare Prescription Drug Benefit: Review and Oversight.”

The PRESIDING OFFICER. Without objection, it is so ordered.

**COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS**

Mrs. MURRAY. Mr. President, I ask unanimous consent that the Committee on Health, Education, Labor, and Pensions be authorized to hold a hearing on the Substance Abuse and Mental Health Services Administration during the session of the Senate on Tuesday, May 8, 2007 at 10 a.m. in room 628 of the Dirksen Senate office building.

The PRESIDING OFFICER. Without objection, it is so ordered.

**COMMITTEE ON THE JUDICIARY**

Mrs. MURRAY. Mr. President, I ask unanimous consent that the Committee on the Judiciary be authorized to meet to conduct a hearing on “Will REAL ID Actually Make Us Safer? An Examination of Privacy and Civil Liberties Concerns” for Tuesday, May 8, 2007 at 10 a.m. in Dirksen Senate Office Building Room 226.

Allen Gilbert, Executive Director, The American Civil Liberties Union of Vermont, Montpelier, VT; Jim Harper, Director, Information Policy Studies, CATO Institute, Washington, DC; Dr. James Carafano, Assistant Director, Kathryn and Shelby Cullom Davis Institute for International Studies, Senior Research Fellow, Douglas and Sarah Allison Center for Foreign Policy Studies, Heritage Foundation, Washington, DC; Bruce Schneider, Founder and Chief Technology Officer, BT Counterpane, Minneapolis, MN; and Janice Kephart, President, 9/11 Security Solutions, LLC, Alexandria, VA.

The PRESIDING OFFICER. Without objection, it is so ordered.

**SELECT COMMITTEE ON INTELLIGENCE**

Mrs. MURRAY. Mr. President, I ask unanimous consent that the Select Committee on Intelligence be authorized to meet during the session of the Senate on May 8, 2007 at 2:30 p.m. to hold a closed hearing.

The PRESIDING OFFICER. Without objection, it is so ordered.